Dr. Kenneth Gruber, is the Founder, former CEO, and current Chief Scientific Officer of Tensive Controls. He is a former NIH Branch Chief, and spent decades in academia as an NIH-funded investigator. He is the inventor on its six patents (3 US & 3 EU) which protect the intellectual property used to develop TCMCB07, as well as other peptide therapeutics. He was the principal investigator on $4.5 million in NIH/NCI SBIR grants. These grants funded the development of the platform technology that produced our lead drug-like MC antagonist peptide (TCMCB07), and the basic drug development research that demonstrated its small and large animal efficacy and preliminary safety. He is responsible for defining the objectives and SOW on Tensive’s grants and CRO contracts, and oversees performance.
Speaking In
[Available On-Demand]
Tensive Controls, Inc. is a late stage preclinical company, that has a first in class MC4R…